Fernández-Hernández Sofía, Hidalgo-León Miguel Ángel, Lacalle-González Carlos, Olivera-Salazar Rocío, Ochieng' Otieno Michael, García-Foncillas Jesús, Martinez-Useros Javier
Department of Pathology, Skien Hospital, Vestfold og Telemark, Ulefossvegen 55, 3710 Skien, Norway.
Translational Oncology Division, OncoHealth Institute, Health Research Institute Fundación Jimenez Diaz, Fundación Jimenez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), 28040 Madrid, Spain.
Biomolecules. 2025 Aug 4;15(8):1119. doi: 10.3390/biom15081119.
Colorectal cancer (CRC) is not only the third most common cancer worldwide, with 1.1 million new cases per year; it is also the second leading cause of cancer death. However, mortality has decreased since 2012 due to early detection programs and better therapeutic approaches. While many patients are diagnosed at an early stage, there is up to 50% relapse after optimal initial treatment. Therefore, it is crucial to explore the mechanism underlying the development of recurrences and metastasis. It is known that tumors release dormant cells that escape chemotherapy and nest in a target organ without proliferating. Under certain circumstances that are not yet entirely clear, they can be activated and metastasize. Therefore, the objective of this work is to explore the detailed mechanisms of dormancy, including early detection of recurrence and therapeutic approaches for the treatment of CRC. The specific objectives are to determine biomarkers that may be useful in identifying dormant cells to detect minimal residual disease (MRD) after surgery and predicting disease progression, as well as evaluating biomarkers that are susceptible to therapeutic intervention.
结直肠癌（CRC）不仅是全球第三大常见癌症，每年有110万新发病例；它也是癌症死亡的第二大主要原因。然而，自2012年以来，由于早期检测计划和更好的治疗方法，死亡率有所下降。虽然许多患者在早期被诊断出来，但在最佳初始治疗后仍有高达50%的复发率。因此，探索复发和转移发生的潜在机制至关重要。已知肿瘤会释放休眠细胞，这些细胞逃避化疗并在靶器官中着床但不增殖。在某些尚未完全清楚的情况下，它们可以被激活并发生转移。因此，这项工作的目的是探索休眠的详细机制，包括复发的早期检测和结直肠癌的治疗方法。具体目标是确定可能有助于识别休眠细胞以检测术后微小残留病（MRD）并预测疾病进展的生物标志物，以及评估易受治疗干预影响的生物标志物。
